NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2026
Back to search
Official data from USPTO
KEDRION BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
06/02/2026
Trademark type
Combined
Nice classes
5, 35, 42, 44
Filing date
02/10/2025
Registration date
06/02/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/02/2026
Last transaction
06/02/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
IT
Examiner
PEISECKI, MARK A
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "KEDRION" having the letter "K" formed partially by a liquid shaped stylization above the wording "BIOPHARMA".
Holders and representatives
Holders
KEDRION S.p.A.
Representatives
Lindsay M.R. Jones Merchant & Gould P.C.
Technical classification
Nice Classes
Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of primary and secondary immunodeficiency disorderscoagulation disordersautoimmune diseases treatable with immunoglobulinsother conditions treatable with plasma derived therapiesbiologic therapiessmall molecules therapies; Pharmaceutical preparations for the treatment of primary and secondary immunodeficiency disorderscoagulation disordersautoimmune diseases treatable with immunoglobulinsother conditions treatable with plasma derived therapiesbiologic therapiessmall molecules therapies
Class 35
Business management; business administration; office functions in the nature of regulatory documentation management for biopharmaceutical activities and pharmaceutical regulatory compliance for others; Business administration in the nature of sales administration
Class 42
Scientific and technological servicesresearchanalysistestingin the field of pharmaceuticalsmedical disorders and the treatment of medical disordersclinical trials; medical and pharmacological research services; providing information and data in relation to medical research and development in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of medical disorders and their treatment; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research; biological researchclinical research and medical research in the field of pharmaceuticals and clinical trials; design and development of computer software for use with medical technology; scientific research on the subject of pharmaceuticals; providing information technology services for the pharmaceutical and healthcare industries; providing information about the results of clinical trials for pharmaceutical products
Class 44
Medical services and small molecule therapy services; medical consultancy in relation to medical and pharmaceutical field; health center services for therapeutical purposes
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/14/2026
PUBO
PUBLISHED FOR OPPOSITION
04/14/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/08/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/18/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/18/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/18/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/18/2026
RFNT
REFUSAL PROCESSED BY IB
10/10/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/24/2025
RFRR
REFUSAL PROCESSED BY MPU
09/24/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/12/2025
CNRT
NON-FINAL ACTION WRITTEN
08/11/2025
DOCK
ASSIGNED TO EXAMINER
08/02/2025
MAFR
APPLICATION FILING RECEIPT MAILED
08/01/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/01/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/31/2025
Continuous trademark protection
Get notified about every new filing that threatens KEDRION BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.